These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 31261805)

  • 1. The Effect of Long-Term Second-Generation Antipsychotics Use on the Metabolic Syndrome Parameters in Jordanian Population.
    Abo Alrob O; Alazzam S; Alzoubi K; Nusair MB; Amawi H; Karasneh R; Rababa'h A; Nammas M
    Medicina (Kaunas); 2019 Jun; 55(7):. PubMed ID: 31261805
    [No Abstract]   [Full Text] [Related]  

  • 2. Changes in neuroendocrine and metabolic hormones induced by atypical antipsychotics in normal-weight patients with schizophrenia.
    Popovic V; Doknic M; Maric N; Pekic S; Damjanovic A; Miljic D; Popovic S; Miljic N; Djurovic M; Jasovic-Gasic M; Dieguez C; Casanueva FF
    Neuroendocrinology; 2007; 85(4):249-56. PubMed ID: 17570902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration.
    Shi L; Ascher-Svanum H; Chiang YJ; Zhao Y; Fonseca V; Winstead D
    BMC Psychiatry; 2009 Dec; 9():80. PubMed ID: 20021664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second-Generation Antipsychotic Utilization and Metabolic Parameter Monitoring in an Inpatient Pediatric Population: A Retrospective Analysis.
    Nolt VD; Kibler AV; Wilkening GL; Fabian TJ
    Paediatr Drugs; 2017 Apr; 19(2):139-146. PubMed ID: 28074349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs.
    Falissard B; Mauri M; Shaw K; Wetterling T; Doble A; Giudicelli A; De Hert M
    Int Clin Psychopharmacol; 2011 Nov; 26(6):291-302. PubMed ID: 21876442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic risk status and second-generation antipsychotic drug selection: a retrospective study of commercially insured patients.
    Morrato EH; Cuffel B; Newcomer JW; Lombardo I; Kamat S; Barron J
    J Clin Psychopharmacol; 2009 Feb; 29(1):26-32. PubMed ID: 19142103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge.
    Marcus SC; Zummo J; Pettit AR; Stoddard J; Doshi JA
    J Manag Care Spec Pharm; 2015 Sep; 21(9):754-68. PubMed ID: 26308223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Metabolic Effects in French-Canadian Children and Adolescents Treated with Second-Generation Antipsychotics in Monotherapy or Polytherapy: A 24-Month Descriptive Retrospective Study.
    Ilies D; Huet AS; Lacourse E; Roy G; Stip E; Amor LB
    Can J Psychiatry; 2017 Dec; 62(12):827-836. PubMed ID: 28673098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk Factors of Metabolic Syndrome Among Patients Receiving Antipsychotics: A Retrospective Study.
    Hammoudeh S; Al Lawati H; Ghuloum S; Iram H; Yehya A; Becetti I; Al-Fakhri N; Ghabrash H; Shehata M; Ajmal N; Amro I; Safdar H; Eltorki Y; Al-Amin H
    Community Ment Health J; 2020 May; 56(4):760-770. PubMed ID: 31884574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid monitoring in patients with schizophrenia prescribed second-generation antipsychotics.
    Weissman EM; Zhu CW; Schooler NR; Goetz RR; Essock SM
    J Clin Psychiatry; 2006 Sep; 67(9):1323-6. PubMed ID: 17017817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sex Differences in Antipsychotic Related Metabolic Functioning in Schizophrenia Spectrum Disorders.
    Kraal AZ; Ward KM; Ellingrod VL
    Psychopharmacol Bull; 2017 May; 47(2):8-21. PubMed ID: 28626268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of a computerized best practice alert system in an outpatient setting on metabolic monitoring in patients on second-generation antipsychotics.
    Cohen S; Bostwick JR; Marshall VD; Kruse K; Dalack GW; Patel P
    J Clin Pharm Ther; 2020 Dec; 45(6):1398-1404. PubMed ID: 32767599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of first-generation antipsychotics versus second-generation antipsychotics on quality of life in schizophrenia: a double-blind, randomised study.
    Gründer G; Heinze M; Cordes J; Mühlbauer B; Juckel G; Schulz C; Rüther E; Timm J;
    Lancet Psychiatry; 2016 Aug; 3(8):717-729. PubMed ID: 27265548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diet and cardiometabolic side effects in children treated with second-generation antipsychotics.
    Barker MK; Sable CM; Montgomery SE; Chow L; Green TJ; Panagiotopoulos C; Devlin AM
    Clin Nutr ESPEN; 2018 Feb; 23():205-211. PubMed ID: 29460800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased Risk of Diabetes Among 6-24-Year-Olds Using Second Generation Antipsychotics.
    Xing S; Lee TA
    J Child Adolesc Psychopharmacol; 2017 Nov; 27(9):782-791. PubMed ID: 28799787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of Metabolic Syndrome in Drug-Naive Adolescents After 12 Months of Second-Generation Antipsychotic Treatment.
    Sjo CP; Stenstrøm AD; Bojesen AB; Frølich JS; Bilenberg N
    J Child Adolesc Psychopharmacol; 2017 Dec; 27(10):884-891. PubMed ID: 28783382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of monitoring for metabolic effects associated with second generation antipsychotics in patients with schizophrenia on public insurance.
    Moeller KE; Rigler SK; Mayorga A; Nazir N; Shireman TI
    Schizophr Res; 2011 Mar; 126(1-3):117-23. PubMed ID: 21168994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes.
    Morrato EH; Newcomer JW; Kamat S; Baser O; Harnett J; Cuffel B
    Diabetes Care; 2009 Jun; 32(6):1037-42. PubMed ID: 19244091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Waist circumference is a sensitive screening tool for assessment of metabolic syndrome risk in children treated with second-generation antipsychotics.
    Panagiotopoulos C; Ronsley R; Kuzeljevic B; Davidson J
    Can J Psychiatry; 2012 Jan; 57(1):34-44. PubMed ID: 22296966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.